Background: PD 0332991, a selective inhibitor of CDK 4/6, prevents cellular DNA synthesis by blocking cell cycle progression. Preclinical studies in a BC cell line panel identified the luminal ER subtype, elevated expression of cyclin D1 and Rb protein, and reduced p16 expression as being associated with sensitivity to PD 0332991 (Finn et al. 2009). Synergistic activity was also observed in vitro when combined with tamoxifen. Based on these observations, a phase 1/2 study in combination with letrozole was initiated. We present results from the randomized phase 2 portion. Methods: The phase 2 portion is a two-part study; Part 1, ER + /HER2-selected; Part 2, further biomarkers. We present results from Part 1. The primary endpoint is progression-free survival (PFS); secondary endpoints include response rate, overall survival, safety, and correlative biomarker studies. Post-menopausal women with ER + /HER2-advanced BC were randomized 1:1 to receive either letrozole 2.5 mg QD plus PD 0332991 125 mg QD on Schedule 3/1 (L + P) or letrozole 2.5 mg QD alone (L). Pts continue on assigned study treatment until disease progression, unacceptable toxicity, or consent withdrawal, and are followed for tumor assessments every 2 months. Results: 66 pts were randomized. Baseline characteristics were balanced between the two arms. As of the data cut-off, median duration of treatment was 47 wks for the L + P arm and 24 wks for the L arm. The most commonly reported treatment-related AEs in the combination arm were neutropenia, leukopenia, and fatigue. The response rate was 27% vs. 23% (out of 26 and 22 pts with measurable disease, L + P vs. L, respectively), clinical benefit rate (PR + SD ≥24 weeks) was 59% vs. 44%, respectively. Two vs. 7 pts had best response of progressive disease for L + P vs. L, respectively. PFS was significantly greater in the L + P arm vs. L (HR = 0.38; 95% CI, 0.17 to 0.86; p = 0.015). There were 20 vs. 8 pts ongoing on assigned treatment. Conclusions: The combination of PD 0332991 and letrozole is well tolerated with encouraging clinical benefit, confirming the preferential sensitivity of ER+ BC observed in preclinical models. Oncology, Mayo Clinic Florida, Jacksonville, FL, UNITED STATES OF AMERICA Background: NKTR-102 is a topoisomerase I inhibitor-polymer conjugate with reduced peak concentration and a continuous concentration profile.
101P SIGNIFICANT ANTITUMOR ACTIVITY IN A RANDOMIZED PHASE 2 STUDY COMPARING 2 SCHEDULES OF NKTR-102 IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC)
A. Oncology, Mayo Clinic Florida, Jacksonville, FL, UNITED STATES OF AMERICA Background: NKTR-102 is a topoisomerase I inhibitor-polymer conjugate with reduced peak concentration and a continuous concentration profile.
Methods:
This was an open-label phase 2 study in pts with advanced MBC; pts were randomized to NKTR-102 given IV at a dose of 145 mg/m 2 over 90-min every 14 or 21 days. The primary endpoint was objective response rate (ORR) by RECIST v1.0; secondary endpoints were safety and PFS. Each schedule followed a 2-stage Simon design (≥1 response in 15 pts was required to enroll an additional 20 pts per schedule). Results: 70 pts (35 per schedule) were randomized from Feb09 -Apr10. Median age: 55 (range 37-83). ECOG PS 0/1: 40%/60%. Median number of prior cytotoxic regimens for metastatic disease (not including hormonal therapy or biologics) was 2. All pts had received prior taxane (T). 89% had received prior anthracyclines (A). 26% had received prior AT/capecitabine (ATC). 61% were ER/PR + ; 30% had TNBC; 86% had visceral metastases. Clinical Development, Nektar Therapeutics, San Francisco, CA, UNITED STATES OF AMERICA Background: NKTR-102 is a next-generation topoisomerase I inhibitor-polymer conjugate that provides continuous exposure to SN-38. A phase 2 trial of single-agent NKTR-102 was conducted in pts with 3rd-line MBC; 2 schedules (q14d; q21d) investigated a dose of 145 mg/m2. ORR was 29% (including 3% CR) with the prior ATC subset demonstrating an ORR of 31%. Dosing q21d was better tolerated; in this arm, median PFS and OS equaled 5.3m and 13.1m, respectively. Trial Design: Pts will be randomized 1:1 to receive either single-agent NKTR-102 or TPC in an open-label, randomized, multicenter Phase 3 study in pts with advanced breast cancer. Key Entry Criteria: Adult females, with ECOG 0 or 1 with adequate liver, kidney and marrow function. All pts must have received prior therapy with ATC (these drugs may have been administered in the neo/adjuvant or locally advanced/ metastatic setting). Prior A is not mandated if contraindicated for a pt. Prior toxicities must have resolved to ≤ Grade 1 (except sensory neuropathy ≤ Grade 2; complete resolution of prior diarrhea). Pts with brain metastases may be eligible, if lesions are stable for prior 3 weeks without steroids.
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Methods: Primary efficacy endpoint is OS. Secondary endpoints include: ORR by RECIST v1.1, clinical benefit rate (ORR + SD > 6 months), PFS and QoL. NKTR-102 is given IV at 145 mg/m2 over 90-min every 21 days without premedications. Pts randomized to TPC receive 1 of the following: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel or nab-paclitaxel (the agent must be available at the treating institution). Pts are stratified by region, prior eribulin and receptor status (TNBC, Her2+ or Other). Target Accrual: ∼840 pts will be required for sufficient events to occur in the planned follow-up time; OS will be compared using a two-sided log-rank test; 1 interim analysis will occur when 50% of the deaths are reported. PK sampling is performed in a subset of pts. Oncology, Pfizer, Milan, ITALY Background: Acquired hormone independent BC cell growth is associated with upregulation of the PI3K/mTOR pathway in vitro and in neo-adjuvant studies of aromatase inhibition (Ghazoui AACR Breast Cancer Symposium, 2011). Preclinical and clinical studies suggest that the combination of hormone therapy and a PI3K/ mTOR inhibitor can restore sensitivity to hormone resistant tumours. Luminal B BCs are more frequently associated with endocrine resistance, hyperactivation of the PI3K signaling pathway, and increased expression of the Ki-67 proliferation marker than Luminal A BCs. This particular population may be a suitable target for PI3K directed therapy. A reduction in Ki-67 in the neo-adjuvant setting by endocrine therapy has been shown to correlate with efficacy of that same therapeutic in the adjuvant setting. Thus, a pre-operative study in high Ki-67-expressing BCs with short term reduction in Ki-67 as a primary endpoint could be used to drive a formally designed adjuvant study with a conventional disease free endpoint. Study design: This pre-operative trial is designed to test the hypothesis that the addition of a PI3K/mTOR antagonist, PF-04691502, to L can reduce Ki-67 levels after six weeks of administration to a greater degree than L alone, thus supporting the concept that the compound might mitigate the intrinsic or acquired resistance to hormonal therapy in a high risk patient population in the adjuvant setting. The trial is being conducted in postmenopausal women with ER positive, HER-2 negative BC. After the lead-in phase in women with advanced BC to assess PF-04691502/L tolerability, a randomized Phase 2 will start in women with early BC selected based on a high level of . 204 patients will be randomized to receive PF-04691502/L or L alone for 6 weeks. Patients will undergo three sequential core-biopsies (baseline, weeks 2 and 6) to compare the changes in Ki-67 value from baseline to the end of the treatments and to test pharmacodynamic effects associated with PI3K/mTOR pathway modulation. This trial is open to enrollment in several European countries. 1 or enterolactone in concentration 1 µM for 5 days had no effect on cell proliferation. Pre-incubation with Knotolan 1 or enterolactone for 2 days followed by incubation with E2 did not stimulate cell proliferation. The capacity of Knotolan 1 to abolish the growth stimulating effect of E2, i.e. to exhibit its antiestrogen properties was similar to the effect of enterolactone. We hypothesized that this effect can be realized in vivo and Knotolan 1 from Abies sibirica can serve as basis for the creation of new plant preparation with protective properties. Disclosure: All authors have declared no conflicts of interest. Patients received erlotinib 150mg daily. Primary endpoint was progression-free survival (PFS). Initially, 9 patients were to be accrued. Results: In total, 9 patients enrolled. Mean age 46.7y, all patients were from kordish ethinicity in west of Iran. Six patients had prior chemotherapy for MBC. Three patients progressed rapidly, median PFS was 3 months for others. However, 1 patient had stable disease for five months. Treatment was well-tolerated. Toxicities in the 6 patients included grade 2 rash, grade 1 diarrhea. Conclusions: Although most patients progressed rapidly, 6/9 patients had prolonged stable disease. This suggests there may be a subset of TN, EGFR positive MBC for whom EGFR-directed therapy may be suitable or that the natural history of their disease was indolent. Future studies to determine molecular and clinical profiles of patients likely to benefit from EGFR-TKI therapy. Disclosure: All authors have declared no conflicts of interest.
